Serina Therapeutics, Inc. (SER)

In the past six months, the FDA cleared the IND application for SER-252, leading to a stock price surge after the initiation of its Phase 1b trial. Serina Therapeutics secured up to $30 million in private placement financing, causing the stock to jump 28% overnight. The company reported its full year 2025 financial results, including a net loss of $19.4 million. The NYSE American accepted the company's plan to regain compliance with listing standards. There was insider selling by the Chief Scientific Officer. The company announced presentations at the 38th Annual Roth Conference and the 5th LNP Formulation & Process Development Summit. Over the past year, the stock has declined by approximately 58.5% to 60.32%, with significant fluctuations between $1.22 and $7.92.

There is no information available regarding demand seasonality for Serina Therapeutics, Inc.'s products and services. As a clinical-stage biotechnology company, traditional product demand seasonality is not currently applicable to the company.

Serina Therapeutics, Inc. is a clinical-stage biotechnology company based in Huntsville, Alabama, specializing in drug delivery systems using its POZ Platform™ technology. The company aims to develop drug candidates for neurology, oncology, and inflammation and is publicly traded on the NYSE American under the ticker symbol SER. The POZ Platform™ is designed to improve the efficacy and safety of small molecules, RNA-based therapeutics, and antibody-based drug conjugates. Serina Therapeutics' major product candidates include SER-252 for advanced Parkinson's disease, SER-227 for long-acting pain relief, SER-214 for early Parkinson's disease and Restless Leg Syndrome, SER-228 for epilepsy, POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases and SER-270 for Tardive dyskinesia.

Serina Therapeutics, Inc. is headquartered in Huntsville, Alabama, on the campus of the HudsonAlpha Institute of Biotechnology. No other specific operational locations are mentioned.

There have been no specific events in the past year that have significantly impacted Serina Therapeutics, Inc.'s brand reputation beyond the typical news flow for a clinical-stage biotechnology company. The company's focus on innovative polymer science and advancing drug delivery for neurological diseases and pain generally contributes to a positive scientific and medical standing.

As of April 2026, Serina Therapeutics, Inc. has 23 institutional owners and shareholders holding 12.50% of the stock. Individual insiders own 10.5% of the shares, private companies own 33.9%, and the general public owns 52%. Major shareholders include Juvenescence Ltd, Juvenescence Us Corp, Vanguard Group Inc, Broadwood Capital Inc, Geode Capital Management, Llc, Linscomb & Williams, Inc. / Linscomb Wealth, Inc., Keel Point, LLC, BlackRock, Inc., Northern Trust Corp, State Street Corp / State Street Global Advisors, Inc., HighTower Advisors, LLC, Steven A. Ledger (CEO), John F. Mauldin, Waverly Advisors LLC, Gregory Bailey, Tacey Viegas and Judith Segall. Shareholders have experienced dilution in the past year, with total shares outstanding growing by 24%.